| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b0321761bd813ca30b0ac348946c4e66
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_98fbb0d7172a7298cc6091af481a7d4d |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55561
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-6031
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-40 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-6424
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0005 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-64
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-08 |
| filingDate |
2021-01-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a56102c034fccf36d2352f8b853644d4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_55332d85a516d87b07ba3a9ac011454b |
| publicationDate |
2021-08-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2021154947-A1 |
| titleOfInvention |
Peptide immunogens targeting pcsk9 and formulations thereof for prevention and treatment of pcsk9-mediated disorders |
| abstract |
The present disclosure is directed to peptide immunogen constructs targeting the catalytic domain of the PCSK9 protein, compositions containing the constructs, antibodies elicited by the constructs, and methods for making and using the constructs and compositions thereof. The disclosed peptide immunogen constructs have more than about 20 amino acids and contain (a) a B cell epitope having about more than about 7 contiguous amino acid residues from the PCSK9 and LDL-R receptor binding regions of the catalytic domain of the PCSK9 protein; (b) a heterologous Th epitope; and (c) an optional heterologous spacer. The disclosed PCSK9 peptide immunogen constructs stimulate the generation of highly specific antibodies directed to PCSK9 sites that are binding to LDL-R to allow for the prevention and/or treatment of patients with PCSK9 mediated disorders including an increased serum level of low-density lipoprotein cholesterol (LDL-C) and CV events. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023161526-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023161528-A1 |
| priorityDate |
2020-01-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |